4NYB image
Entry Detail
PDB ID:
4NYB
Keywords:
Title:
Crystal structure of the E. coli thiM riboswitch in complex with (4-(1,2,3-thiadiazol-4-yl)phenyl)methanamine
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2013-12-10
Release Date:
2014-06-04
Method Details:
Experimental Method:
Resolution:
3.10 Å
R-Value Free:
0.24
R-Value Work:
0.18
Space Group:
P 32 1 2
Macromolecular Entities
Polymer Type:polyribonucleotide
Description:thiM TPP riboswitch
Chain IDs:A
Chain Length:83
Number of Molecules:1
Biological Source:Escherichia coli
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
A23 A A ?
Primary Citation
Validating Fragment-Based Drug Discovery for Biological RNAs: Lead Fragments Bind and Remodel the TPP Riboswitch Specifically.
Chem.Biol. 21 591 595 (2014)
PMID: 24768306 DOI: 10.1016/j.chembiol.2014.03.007

Abstact

Thiamine pyrophosphate (TPP) riboswitches regulate essential genes in bacteria by changing conformation upon binding intracellular TPP. Previous studies using fragment-based approaches identified small molecule "fragments" that bind this gene-regulatory mRNA domain. Crystallographic studies now show that, despite having micromolar Kds, four different fragments bind the TPP riboswitch site-specifically, occupying the pocket that recognizes the aminopyrimidine of TPP. Unexpectedly, the unoccupied site that would recognize the pyrophosphate of TPP rearranges into a structure distinct from that of the cognate complex. This idiosyncratic fragment-induced conformation, also characterized by small-angle X-ray scattering and chemical probing, represents a possible mechanism for adventitious ligand discrimination by the riboswitch, and suggests that off-pathway conformations of RNAs can be targeted for drug development. Our structures, together with previous screening studies, demonstrate the feasibility of fragment-based drug discovery against RNA targets.

Legend

Protein

Chemical

Disease

Primary Citation of related structures